- Home
- SLM vs LEGN Comparison
SLM vs LEGN Comparison
Compare SLM & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLM
- LEGN
- Stock Information
- Founded
- SLM 1972
- LEGN 2014
- Country
- SLM United States
- LEGN United States
- Employees
- SLM N/A
- LEGN N/A
- Industry
- SLM Finance: Consumer Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- SLM Finance
- LEGN Health Care
- Exchange
- SLM Nasdaq
- LEGN Nasdaq
- Market Cap
- SLM 6.7B
- LEGN 5.4B
- IPO Year
- SLM N/A
- LEGN 2020
- Fundamental
- Price
- SLM $31.23
- LEGN $38.80
- Analyst Decision
- SLM Buy
- LEGN Strong Buy
- Analyst Count
- SLM 11
- LEGN 11
- Target Price
- SLM $34.18
- LEGN $74.60
- AVG Volume (30 Days)
- SLM 2.3M
- LEGN 1.4M
- Earning Date
- SLM 07-24-2025
- LEGN 08-11-2025
- Dividend Yield
- SLM 1.67%
- LEGN N/A
- EPS Growth
- SLM N/A
- LEGN N/A
- EPS
- SLM 1.97
- LEGN N/A
- Revenue
- SLM $1,206,861,000.00
- LEGN $728,303,000.00
- Revenue This Year
- SLM $7.32
- LEGN $65.33
- Revenue Next Year
- SLM $17.98
- LEGN $54.68
- P/E Ratio
- SLM $15.85
- LEGN N/A
- Revenue Growth
- SLM N/A
- LEGN 112.46
- 52 Week Low
- SLM $19.39
- LEGN $27.34
- 52 Week High
- SLM $34.97
- LEGN $59.62
- Technical
- Relative Strength Index (RSI)
- SLM 37.38
- LEGN 47.38
- Support Level
- SLM $30.39
- LEGN $38.53
- Resistance Level
- SLM $33.49
- LEGN $45.30
- Average True Range (ATR)
- SLM 0.96
- LEGN 1.76
- MACD
- SLM -0.21
- LEGN -0.61
- Stochastic Oscillator
- SLM 25.77
- LEGN 9.73
About SLM SLM Corporation
SLM Corp is an education solutions company. It business is to originate and service loans to students and their families to finance the cost of their education. The provide Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.